ATSN-101

· Atsena Therapeutics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ATSN-101, covering 2024-02-20 to 2024-02-20. Get the full timeline:

Most recent: Clinical Trial Update: Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D [Phase 1, Phase 2]

See pricing